Clinical trials: sponsored by ImmunityBio, Inc.
B-ALL, Leukemia
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
This is a phase 1, open-label study to evaluate the safety and efficacy of CD19 t-haNK in patients with B-cell acute lymphoblastic leukemia. Up to 10 patients will receive at least 1 dose of study drug.
- Trial name
- NCT07556757
- Testing
- CD19 t-haNK
- Where
- 2 sites in South Africa
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
Non Muscle Invasive Bladder Cancer
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.
- Trial name
- NCT05981131
- Testing
- N803 plus Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
- Trial name
- NCT02049905
- Testing
- Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 433 people
- Sponsor
- ImmunityBio, Inc.
COVID-19
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.
- Trial name
- NCT06022224
- Testing
- hAd5-S-Fusion+N-ETSD
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been…
- Conditions
- Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
- Trial name
- NCT01514188
- Testing
- INNO-206, Doxorubicin
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 126 people
- Sponsor
- ImmunityBio, Inc.
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
This is a Phase 1 open-label study to study the safety and activity of aldoxorubicin with ifosfamide/mesna in subjects with metastatic, advanced, unresectable soft tissue sarcoma.
- Trial name
- NCT02235701
- Testing
- 170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Metastatic Solid Tumors
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
This is a Phase 1 study to investigate the safety and activity of aldoxorubicin plus gemcitabine in Subjects with solid tumors.
- Trial name
- NCT02235688
- Testing
- aldoxorubicin, gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- ImmunityBio, Inc.